Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "China"

382 News Found

Illumina and Sequoia Capital China selects startups for Genomics
Startup | November 18, 2021

Illumina and Sequoia Capital China selects startups for Genomics

First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics


Dr Reddy’s launch anti-cancer drug in China
Drug Approval | October 13, 2021

Dr Reddy’s launch anti-cancer drug in China

Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market


Merck’s KEYTRUDA receives China approval for Esophageal cancer
Drug Approval | September 09, 2021

Merck’s KEYTRUDA receives China approval for Esophageal cancer

The medicine is now approved for eight indications across five different types of cancer in China.


Anti-dumping duty proposed on Vitamin C from China for five years
News | September 07, 2021

Anti-dumping duty proposed on Vitamin C from China for five years

The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports


Lonza to establish manufacturing facility in Guangzhou, China
News | August 25, 2021

Lonza to establish manufacturing facility in Guangzhou, China

The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services


Novartis secures new approval in China for Cosentyx in pediatric psoriasis
Drug Approval | August 18, 2021

Novartis secures new approval in China for Cosentyx in pediatric psoriasis

Cosentyx is a proven treatment, supported by long-term five-year sustained efficacy and safety data across several inflammatory conditions and with more than 500,000 patients treated worldwide since launch


Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China
Biotech | August 11, 2021

Penpulimab Monoclonal Antibody (PD-1) Obtains Marketing Approval in China

The approval is based on a multi-centre, single-arm, open-label pivotal clinical trial


China NMPA approves phase II clinical trial of ASC40
Policy | August 09, 2021

China NMPA approves phase II clinical trial of ASC40

Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne


India Initiates anti dumping probe against import of ATS-8 from China
Policy | August 04, 2021

India Initiates anti dumping probe against import of ATS-8 from China

Arch Pharma Labs has filed the application


Lonza to expand API manufacturing facility in Nansha, China
News | June 28, 2021

Lonza to expand API manufacturing facility in Nansha, China

The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022